Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
There is a growing body of data that continues to expand our understanding of IBSRELA and how it works to provide symptomatic relief.
- There is a growing body of data that continues to expand our understanding of IBSRELA and how it works to provide symptomatic relief.
- These data provide additional evidence of IBSRELA’s safety and efficacy, bringing much needed relief to those living with IBS-C,” said Laura Williams, MD, MPH, chief medical officer of Ardelyx.
- The Phase 3 T3MPO-2 trial randomized patients to tenapanor 50 mg twice a day or matched placebo for 26 weeks of treatment.
- This post hoc analysis found that IBSRELA-treated patients with IBS-C reported a reduction in abdominal symptom scores compared to placebo.